[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"blog-post-gip-glp1-dual-agonists-brenipatide-vk2735-enicepatide-zh":3},{"_path":4,"_dir":5,"_draft":6,"_partial":6,"_locale":7,"title":8,"description":9,"cat":10,"icon":11,"accent":12,"date":13,"dateLabel":14,"updated":13,"read":15,"author":16,"image":17,"faq":18,"body":40,"_type":995,"_id":996,"_source":997,"_file":998,"_stem":999,"_extension":1000},"\u002Fblog\u002Fzh\u002Fgip-glp1-dual-agonists-brenipatide-vk2735-enicepatide","zh",false,"","Brenipatide、VK2735 和 Enicepatide：三款 GIP\u002FGLP-1 双受体激动剂在 2026 年 9 月公布新数据","这是一般性科普信息，不是医疗建议，也不是鼓励你去获取或使用任何物质。Brenipatide、VK2735 和 Enicepatide 都是在研药物，在任何地方都未获批准，既不能合法开具处方，也不能合法购买。本文不提供任何剂量、联用或获取方面的指引。下文出现的剂量只是试验组的名称，不是任何人应当使用的量。这些数字来自设计各不相同的独立研究，不是头对头比较。","研究","tabler:flask-2","#6D5FC7","2026-09-26","2026年9月","13 分钟","myPeptides Team","\u002Fassets\u002Fgip-glp1-dual-trio_hero.png",[19,22,25,28,31,34,37],{"q":20,"a":21},"Brenipatide 是什么？","Brenipatide 的研发代号是 LY3537031，是礼来的一款在研 GIP\u002FGLP-1 双受体激动剂，目前在任何地方都未获批准。它的一期研究数据以壁报形式在 Psych Congress 2026 上展示。礼来表示，研究方向是物质使用障碍、精神疾病和免疫性疾病，而不是体重。",{"q":23,"a":24},"Brenipatide 在临床试验中登记了哪些适应证？","截至 2026 年 9 月 26 日，ClinicalTrials.gov 上共有十二项 Brenipatide 的二期或三期研究。酒精使用障碍和重度抑郁症在做三期研究。双相情感障碍、精神分裂症、阿片类物质使用障碍、戒烟后复吸、肠易激综合征的两种主要类型、哮喘和慢阻肺在做二期研究。登记信息只说明正在测试什么，并不说明这款药对其中任何一种疾病有效。",{"q":26,"a":27},"VK2735 的维持研究测了什么？","Viking 让约 180 名肥胖成年人每周注射一次 VK2735，持续 21 周。之后大多数人进入为期 12 周的维持方案之一：继续每周一次、每两周一次、每月一次，或改用安慰剂。研究要回答的问题是：第 21 周时减掉的体重，到第 33 周还能保住多少。",{"q":29,"a":30},"VK2735 减少注射频率后，减掉的体重保住了多少？","据 Viking 公布，每两周一次的各组在第 33 周保住了第 21 周减重的 82.5% 到 96.7%。每月一次的各组保住了 82.3% 到 90.2%，而改用安慰剂的人只保住 61.1%。每组只有 10 到 16 名受试者。",{"q":32,"a":33},"罗氏公布的 Enicepatide 2 型糖尿病数据是什么？","在为期 48 周的二期试验 CT-388-104 中，罗氏公布了最高试验剂量的结果。糖化血红蛋白（HbA1c）从基线 8.1% 下降了 2.65 个百分点，平均体重下降 15.5%。新闻稿没有说明这些数字是否扣除了安慰剂效应，也没有给出较低剂量的数据。",{"q":35,"a":36},"Brenipatide、VK2735 和 Enicepatide 的半衰期与替尔泊肽相比如何？","根据美国说明书，替尔泊肽的半衰期约为 5 天。已公布的数值是：Brenipatide 9.08 到 12.5 天，VK2735 单次给药后约 7 到 10 天，Enicepatide 约 5 到 6 天。这些数字来自设计不同的研究，只能看出大致方向，不能精确排序。",{"q":38,"a":39},"Brenipatide、VK2735 或 Enicepatide 获批了吗？体育比赛中允许使用吗？","三者在任何地方都未获批准。凡是未经任何政府批准用于人体治疗的物质，都归入世界反兴奋剂机构（WADA）禁用清单的 S0 类，任何时候都禁用。",{"type":41,"children":42,"toc":975},"root",[43,50,106,113,126,131,160,166,175,185,195,205,215,225,231,242,251,261,271,285,295,303,308,317,323,332,342,352,362,368,387,432,437,444,449,455,460,657,662,669,674,679,692,697,703,707,712,716,721,725,730,734,739,743,748,752,757,761,766],{"type":44,"tag":45,"props":46,"children":47},"element","p",{},[48],{"type":49,"value":9},"text",{"type":44,"tag":45,"props":51,"children":52},{},[53,55,66,68,77,79,88,90,96,98,104],{"type":49,"value":54},"2026 年 9 月的同一周里，三家公司公布了新的人体数据，涉及的药物作用于同一对肠道激素受体。礼来在一场精神病学大会上展示了一张关于 ",{"type":44,"tag":56,"props":57,"children":58},"strong",{},[59],{"type":44,"tag":60,"props":61,"children":63},"a",{"href":62},"\u002Fpeptides\u002Fbrenipatide",[64],{"type":49,"value":65},"Brenipatide",{"type":49,"value":67}," 的壁报。Viking Therapeutics 公布了 ",{"type":44,"tag":56,"props":69,"children":70},{},[71],{"type":44,"tag":60,"props":72,"children":74},{"href":73},"\u002Fpeptides\u002Fvk2735",[75],{"type":49,"value":76},"VK2735",{"type":49,"value":78}," 一项维持研究的结果。罗氏则宣布了 ",{"type":44,"tag":56,"props":80,"children":81},{},[82],{"type":44,"tag":60,"props":83,"children":85},{"href":84},"\u002Fpeptides\u002Fenicepatide",[86],{"type":49,"value":87},"Enicepatide",{"type":49,"value":89}," 在 2 型糖尿病中的二期结果。三者都是 GIP 和 GLP-1 受体的双重激动剂，这也是已获批药物",{"type":44,"tag":60,"props":91,"children":93},{"href":92},"\u002Fpeptides\u002Ftirzepatide",[94],{"type":49,"value":95},"替尔泊肽",{"type":49,"value":97},"背后的原理。它们的作用机制相同，但三项研究问的问题截然不同，这正是本文的主线。想先大致了解这类药物，可以看我们关于 ",{"type":44,"tag":60,"props":99,"children":101},{"href":100},"\u002Fgip-glp1-dual-agonists",[102],{"type":49,"value":103},"GIP\u002FGLP-1 双受体激动剂",{"type":49,"value":105},"的概述。",{"type":44,"tag":107,"props":108,"children":110},"h2",{"id":109},"为什么-gip-是共同的线索",[111],{"type":49,"value":112},"为什么 GIP 是共同的线索",{"type":44,"tag":45,"props":114,"children":115},{},[116,118,124],{"type":49,"value":117},"GLP-1 和 GIP 是肠道在进食后释放的两种激素。血糖升高时，两者都会帮助胰腺分泌胰岛素。GLP-1 还会减慢胃排空，并作用于大脑中调控食欲的区域，",{"type":44,"tag":60,"props":119,"children":121},{"href":120},"\u002Fpeptides\u002Fsemaglutide",[122],{"type":49,"value":123},"司美格鲁肽",{"type":49,"value":125},"这类药物就只建立在 GLP-1 之上。GIP 长期被看作不太有用的那一半。替尔泊肽用一个分子同时激活两种受体，改变了这种看法。",{"type":44,"tag":45,"props":127,"children":128},{},[129],{"type":49,"value":130},"礼来的壁报补充了一个对本文很关键的细节。壁报指出，GIP 和 GLP-1 受体远不止存在于胰腺，在肠道、心脏、肺、肾脏、肝脏、脂肪组织和大脑中都有分布。正因为分布这么广，这类受体激动剂才被拿来研究那些和代谢相去甚远的疾病，这是壁报给出的理由。这个推理在患者身上是否成立，目前仍是未解的问题。",{"type":44,"tag":45,"props":132,"children":133},{},[134,136,142,144,150,152,158],{"type":49,"value":135},"三个分子之间也各有不同。罗氏把 Enicepatide 描述为具有信号偏向性，意思是它被设计成优先触发细胞内的某一种信号，而不是促使受体被内吞回细胞里。我们",{"type":44,"tag":60,"props":137,"children":139},{"href":138},"\u002Fblog\u002Fenicepatide-ct-388-roche",[140],{"type":49,"value":141},"之前关于 Enicepatide 的文章",{"type":49,"value":143},"解释过这种设计。在礼来和 Viking 的公开资料中，未能检索到这两个分子的完整化学结构。通讯 ",{"type":44,"tag":145,"props":146,"children":147},"em",{},[148],{"type":49,"value":149},"The Incretin Space",{"type":49,"value":151}," 的作者根据专利和结构检索提出了两个假说。第一个假说是，Brenipatide 类似于去掉了胰高血糖素受体部分的",{"type":44,"tag":60,"props":153,"children":155},{"href":154},"\u002Fpeptides\u002Fretatrutide",[156],{"type":49,"value":157},"瑞他鲁肽",{"type":49,"value":159},"。第二个假说是，VK2735 可能和替尔泊肽共用同一条氨基酸链，但带有一条末端为膦酸基团的脂肪酸侧链。这两个假说都未能在公司发布的资料中得到证实，因此都仍属推测。",{"type":44,"tag":107,"props":161,"children":163},{"id":162},"brenipatide一款不以减重为开发方向的双激动剂",[164],{"type":49,"value":165},"Brenipatide：一款不以减重为开发方向的双激动剂",{"type":44,"tag":45,"props":167,"children":168},{},[169,173],{"type":44,"tag":60,"props":170,"children":171},{"href":62},[172],{"type":49,"value":65},{"type":49,"value":174},"（代号 LY3537031）的临床数据，以 P-175 号壁报的形式在 Psych Congress 2026 上展示。这次大会于 9 月 15 日至 19 日在新奥尔良举行。对一款 GIP\u002FGLP-1 药物来说，这个场合并不寻常。壁报写明的目标，是为物质使用障碍、精神疾病和免疫性疾病寻找给药方案，而不是为肥胖或糖尿病。",{"type":44,"tag":45,"props":176,"children":177},{},[178,183],{"type":44,"tag":56,"props":179,"children":180},{},[181],{"type":49,"value":182},"研究设计。",{"type":49,"value":184}," NCT06606106 是一项一期多次递增剂量研究，研究者和受试者都不知道分组，停药后随访 8 周。A 部分纳入体重指数（BMI）在 27 到 45 之间的人，B 部分纳入 BMI 在 22 到 26.9 之间的人。C 部分纳入同一较低 BMI 范围内的日本裔或华裔受试者。根据壁报中的表格，184 人接受了 Brenipatide，28 人接受了安慰剂。研究测试了五个剂量水平，每周注射一次，直到第 78 天，最高剂量只在 A 部分使用。壁报展示的是已完成队列的中期数据。",{"type":44,"tag":45,"props":186,"children":187},{},[188,193],{"type":44,"tag":56,"props":189,"children":190},{},[191],{"type":49,"value":192},"体重。",{"type":49,"value":194}," 礼来把体重变化当作替代指标，用来确认药物在各个剂量下都有药理活性。据壁报显示，体重变化随剂量增加而增大。结果只以图表呈现，没有印出具体数字，所以本文不给出数值。图表还显示，停药后各组体重都出现了回升。一些二手来源从曲线上读取了数值，但礼来并未公布这些数字，我们不予采用。",{"type":44,"tag":45,"props":196,"children":197},{},[198,203],{"type":44,"tag":56,"props":199,"children":200},{},[201],{"type":49,"value":202},"药代动力学。",{"type":49,"value":204}," 药代动力学研究的是身体如何吸收和清除药物。壁报报告的平均半衰期为 9.08 到 12.5 天，峰谷比在 1.35 到 1.59 之间。峰谷比接近 1，意味着两次每周注射之间血药浓度几乎不怎么波动。药物暴露量与剂量成比例上升，不同族裔之间看起来相近。壁报没有给出 Tmax，也就是注射后达到最高血药浓度所需的时间。",{"type":44,"tag":45,"props":206,"children":207},{},[208,213],{"type":44,"tag":56,"props":209,"children":210},{},[211],{"type":49,"value":212},"耐受性。",{"type":49,"value":214}," 研究中没有报告严重不良事件或死亡。使用 Brenipatide 的受试者中有四人（2.2%）因不良事件停药。Brenipatide 组和安慰剂组都有 25% 的受试者出现胃肠道不良事件。恶心、呕吐和腹泻都是轻度的，只有两次恶心为中度，而且都没有导致停药。有一项发现格外醒目。15.2% 使用 Brenipatide 的人报告了感觉异常（dysaesthesia），也就是皮肤灼烧、刺痛之类的异常感觉，安慰剂组则无人报告。除一例中度外，其余均为轻度，全部已经消退，其中一例导致停药。这项研究规模小，受试者又以男性为主，这些比例只能算初步结果。",{"type":44,"tag":45,"props":216,"children":217},{},[218,223],{"type":44,"tag":56,"props":219,"children":220},{},[221],{"type":49,"value":222},"试验项目。",{"type":49,"value":224}," 2026 年 9 月 26 日在 ClinicalTrials.gov 上检索，可以找到十二项 Brenipatide 的二期或三期研究。其中四项三期研究针对酒精使用障碍和重度抑郁症。八项二期研究中，有四项针对双相情感障碍、精神分裂症、阿片类物质使用障碍和戒烟后复吸。另外四项针对便秘型或腹泻型肠易激综合征、哮喘以及慢性阻塞性肺疾病（慢阻肺，COPD）。这份清单是登记平台上的检索结果，只说明正在测试什么。针对这些疾病中的任何一种，都未能检索到疗效结果。",{"type":44,"tag":107,"props":226,"children":228},{"id":227},"vk2735维持研究测了什么",[229],{"type":49,"value":230},"VK2735：维持研究测了什么",{"type":44,"tag":45,"props":232,"children":233},{},[234,236,240],{"type":49,"value":235},"Viking Therapeutics 的 ",{"type":44,"tag":60,"props":237,"children":238},{"href":73},[239],{"type":49,"value":76},{"type":49,"value":241}," 已经进入肥胖症的三期研究。VANQUISH-1（NCT07104500）纳入肥胖人群，VANQUISH-2（NCT07104383）纳入同时患有肥胖和 2 型糖尿病的人群。据 Viking 的演示资料，两项研究都已完成入组，结果预计在 2027 年下半年公布。2026 年 9 月 22 日公布的数据来自另一项研究 VK2735-102，它问的问题更窄：注射频率降低以后，减掉的体重能保住多少？",{"type":44,"tag":45,"props":243,"children":244},{},[245,249],{"type":44,"tag":56,"props":246,"children":247},{},[248],{"type":49,"value":182},{"type":49,"value":250}," 据 Viking 介绍，约 180 名 BMI 至少为 30、没有其他重大疾病的成年人参加了研究。在诱导期，所有用药组都接受 21 次每周注射，剂量逐步上调。在第 21 周到第 33 周的维持期，大多数受试者换到新的给药方案。可选方案有四种：继续每周一次、较低剂量每两周一次、每月一次，或改用安慰剂。之后还有 5 周的随访期。ClinicalTrials.gov 把 VK2735-102 登记为一项双盲、安慰剂对照的一期研究（NCT07838740）。目前公布的结果来自其第一部分，只测试了注射剂型。",{"type":44,"tag":45,"props":252,"children":253},{},[254,259],{"type":44,"tag":56,"props":255,"children":256},{},[257],{"type":49,"value":258},"诱导期。",{"type":49,"value":260}," 到第 21 周，四个剂量组的平均体重下降了 16.3% 到 18.7%，安慰剂组为 0.1%。人数最多的 17.5 mg 组有 118 名受试者，体重下降 17.8%。Viking 的演示资料统计了 143 名在第 21 周称过体重的 VK2735 使用者。其中 90% 的人减掉了至少十分之一的体重，安慰剂组则没有一个人做到。诱导期内有 13% 的受试者提前退出，1% 因不良事件停药。在使用 VK2735 的人中，42% 报告恶心，27% 呕吐，20% 腹泻，11% 便秘。Viking 称其剂量递增方案为加速方案。",{"type":44,"tag":45,"props":262,"children":263},{},[264,269],{"type":44,"tag":56,"props":265,"children":266},{},[267],{"type":49,"value":268},"继续每周注射。",{"type":49,"value":270}," 有 13 人留在 17.5 mg 组，继续每周注射直到第 33 周。他们的平均体重下降达到 21.7%，而 15 人的安慰剂组最终比基线高出 0.3%。Viking 报告说，这条曲线还没有走平。只有 13 个人，这个数字的不确定性很大。",{"type":44,"tag":272,"props":273,"children":284},"mono-line-chart",{"caption":274,"highlight":275,"series":276,"table-label":277,"title":278,"unit":279,"x-label":280,"y-label":281,"y-max":282,"y-min":283},"只显示 Viking 以数字形式公布的数据点。第 21 周的数值来自 17.5 mg 诱导组全部 118 人，第 33 周的数值来自继续每周注射的 13 人。一期研究，数据来自不同研究，不是头对头比较。来源：Viking Therapeutics，顶线结果演示资料，2026 年 9 月。","17.5 mg 组","[{\"label\":\"17.5 mg 组\",\"points\":[[0,0],[21,-17.8],[33,-21.7]]},{\"label\":\"安慰剂组\",\"points\":[[0,0],[21,-0.1],[33,0.3]]}]","数据表","VK2735-102：17.5 mg 组与安慰剂组的体重变化","%","周","体重变化","2","-25",[],{"type":44,"tag":45,"props":286,"children":287},{},[288,293],{"type":44,"tag":56,"props":289,"children":290},{},[291],{"type":49,"value":292},"维持期。",{"type":49,"value":294}," Viking 用第 33 周仍然保留的、第 21 周已减体重的比例来表示结果。在每两周一次的各组中，10 mg 组为 96.7%，7.5 mg 组为 89.9%，5 mg 组为 82.5%。在每月一次的各组中，17.5 mg 组为 90.2%，20 mg 组为 85.8%。随后是 22.5 mg、15 mg 和 10 mg 组，分别为 84.9%、84.1% 和 82.3%。从每周注射换成安慰剂的人保住了 61.1%，也就是说，他们在 12 周内把减掉的体重涨回了将近五分之二。每个维持组只有 10 到 16 名受试者，组与组之间的小差别说明不了多少问题。",{"type":44,"tag":296,"props":297,"children":302},"mono-bar-chart",{"bars":298,"caption":299,"highlight":300,"title":301,"unit":279},"[{\"label\":\"每 2 周一次，10 mg 组\",\"value\":96.7,\"note\":\"n = 12\"},{\"label\":\"每月一次，17.5 mg 组\",\"value\":90.2,\"note\":\"n = 11\"},{\"label\":\"每 2 周一次，7.5 mg 组\",\"value\":89.9,\"note\":\"n = 13\"},{\"label\":\"每月一次，20 mg 组\",\"value\":85.8,\"note\":\"n = 14\"},{\"label\":\"每月一次，22.5 mg 组\",\"value\":84.9,\"note\":\"n = 10\"},{\"label\":\"每月一次，15 mg 组\",\"value\":84.1,\"note\":\"n = 14\"},{\"label\":\"每 2 周一次，5 mg 组\",\"value\":82.5,\"note\":\"n = 12\"},{\"label\":\"每月一次，10 mg 组\",\"value\":82.3,\"note\":\"n = 16\"},{\"label\":\"换用安慰剂\",\"value\":61.1,\"note\":\"n = 27\"}]","在 21 周每周注射之后进行的 12 周维持期，每组 10 到 16 人。一期研究，同一研究的不同分组，不是与其他药物的头对头比较。来源：Viking Therapeutics，顶线结果演示资料，2026 年 9 月。","换用安慰剂","VK2735-102：第 33 周时仍保留的第 21 周减重比例",[],{"type":44,"tag":45,"props":304,"children":305},{},[306],{"type":49,"value":307},"维持期内，胃肠道不适明显减少。每两周一次的各组中，5% 的人报告恶心，3% 报告呕吐，安慰剂组分别为 0% 和 7%。每月一次的各组中，4.5% 报告恶心，8% 报告呕吐。Viking 表示，这些比例与安慰剂相比没有实质差别。这种下降有一部分在意料之中，因为诱导期耐受不佳的人在第 21 周之前就已经退出了。",{"type":44,"tag":45,"props":309,"children":310},{},[311],{"type":44,"tag":312,"props":313,"children":316},"img",{"alt":314,"src":315},"风格化的风景：尖锐嶙峋的山峰耸立在低矮圆润的沙丘之上，旁边是一片平静的湖面","\u002Fassets\u002Fgip-glp1-dual-trio_illustration.png",[],{"type":44,"tag":107,"props":318,"children":320},{"id":319},"enicepatide2-型糖尿病试验的结果",[321],{"type":49,"value":322},"Enicepatide：2 型糖尿病试验的结果",{"type":44,"tag":45,"props":324,"children":325},{},[326,330],{"type":44,"tag":60,"props":327,"children":328},{"href":84},[329],{"type":49,"value":87},{"type":49,"value":331}," 原名 CT-388，是罗氏收购 Carmot Therapeutics 时得到的。2026 年 1 月，罗氏公布了在非糖尿病人群中进行的肥胖试验 NCT06525935 的结果。48 周时，最高试验剂量带来的体重下降在扣除安慰剂后，按疗效估计目标（efficacy estimand）计算为 22.5%，按治疗方案估计目标（treatment-regimen estimand）计算为 18.3%。两项肥胖症三期试验 ENITH-1（NCT07351045）和 ENITH-2（NCT07351058）目前正在招募受试者。",{"type":44,"tag":45,"props":333,"children":334},{},[335,340],{"type":44,"tag":56,"props":336,"children":337},{},[338],{"type":49,"value":339},"新的试验。",{"type":49,"value":341}," 2026 年 9 月 22 日，罗氏就 CT-388-104（NCT06628362）发布了一则临时公告。这是一项随机、双盲、安慰剂对照的二期试验，为期 48 周，纳入 447 名患有 2 型糖尿病且超重或肥胖的成年人。据罗氏介绍，试验达到了两个主要终点，也就是事先定好的两项主要测量结果：血糖和体重都随剂量增加而下降。",{"type":44,"tag":45,"props":343,"children":344},{},[345,350],{"type":44,"tag":56,"props":346,"children":347},{},[348],{"type":49,"value":349},"具体数字。",{"type":49,"value":351}," 罗氏只公布了最高试验剂量 24 mg 组的疗效数据。糖化血红蛋白（HbA1c，反映过去几个月的平均血糖）从平均基线 8.1% 下降了 2.65 个百分点。在起始值高于 8.5% 的受试者中，下降了 4.13 个百分点。第 48 周时，该组 90% 的人 HbA1c 降到 6.5% 或以下，62% 低于 5.7%，也就是被视为正常的范围。平均体重下降 15.5%，据罗氏说还没有进入平台期。在所有 Enicepatide 组中，2.0% 的人因不良事件停药，安慰剂组无人停药。最常见的不良事件是胃肠道反应，大多为轻度到中度。",{"type":44,"tag":45,"props":353,"children":354},{},[355,360],{"type":44,"tag":56,"props":356,"children":357},{},[358],{"type":49,"value":359},"新闻稿没有说清的地方。",{"type":49,"value":361}," 公告没有说明 15.5% 和 2.65 个百分点是否扣除了安慰剂效应，也没有说明采用了哪种估计目标。安慰剂组的结果和较低剂量的数字都没有公布。2 型糖尿病患者的减重幅度通常小于非糖尿病人群，替尔泊肽的数据也显示了这一规律。因此，15.5% 不能直接拿来和肥胖试验中的 22.5% 相比。罗氏计划在 2027 年上半年启动血糖控制方面的三期项目，以及心血管结局试验。",{"type":44,"tag":107,"props":363,"children":365},{"id":364},"半衰期tmax-与耐受性药代动力学能说明什么",[366],{"type":49,"value":367},"半衰期、Tmax 与耐受性：药代动力学能说明什么",{"type":44,"tag":45,"props":369,"children":370},{},[371,373,378,380,385],{"type":49,"value":372},"有两个药代动力学数值决定了每周一次的注射在体内如何表现。",{"type":44,"tag":56,"props":374,"children":375},{},[376],{"type":49,"value":377},"半衰期",{"type":49,"value":379},"是体内药量减少一半所需的时间。",{"type":44,"tag":56,"props":381,"children":382},{},[383],{"type":49,"value":384},"Tmax",{"type":49,"value":386}," 是从注射到血药浓度达到最高点所需的时间。半衰期长、Tmax 晚，血药浓度曲线就比较平缓；Tmax 短，每次注射后就会出现更尖的高峰。血药浓度更平缓是否意味着胃肠道不适更少，是好几家公司都提到的一个假说。这个假说还没有在直接对比中检验过。",{"type":44,"tag":388,"props":389,"children":390},"ul",{},[391,402,412,422],{"type":44,"tag":392,"props":393,"children":394},"li",{},[395,400],{"type":44,"tag":56,"props":396,"children":397},{},[398],{"type":49,"value":399},"替尔泊肽。",{"type":49,"value":401}," 根据美国处方信息，它的半衰期约为 5 天，注射后 8 到 72 小时达到血药浓度峰值。",{"type":44,"tag":392,"props":403,"children":404},{},[405,410],{"type":44,"tag":56,"props":406,"children":407},{},[408],{"type":49,"value":409},"Brenipatide。",{"type":49,"value":411}," 壁报报告的平均半衰期为 9.08 到 12.5 天。未能检索到 Tmax 数据。",{"type":44,"tag":392,"props":413,"children":414},{},[415,420],{"type":44,"tag":56,"props":416,"children":417},{},[418],{"type":49,"value":419},"VK2735。",{"type":49,"value":421}," Viking 2023 年的一期公告给出，单次给药后的半衰期约为 170 到 250 小时，大致相当于 7 到 10 天。Tmax 约为 75 到 90 小时。",{"type":44,"tag":392,"props":423,"children":424},{},[425,430],{"type":44,"tag":56,"props":426,"children":427},{},[428],{"type":49,"value":429},"Enicepatide。",{"type":49,"value":431}," Chakravarthy 等人发表的一期研究报告，单次给药后的半衰期为 123 到 139 小时。多次给药后为 130 到 151 小时。这大约相当于 5 到 6 天，与替尔泊肽相近。较高剂量下 Tmax 约为 24 小时，最低单次剂量下约为 72 小时。",{"type":44,"tag":45,"props":433,"children":434},{},[435],{"type":49,"value":436},"下图显示的是每个已公布范围的上限。来源以天为单位的数值换算成了小时，所以 12.5 天就是 300 小时。完整的范围见上面的列表和下文的表格。",{"type":44,"tag":296,"props":438,"children":443},{"bars":439,"caption":440,"highlight":65,"title":441,"unit":442},"[{\"label\":\"Brenipatide\",\"value\":300,\"note\":\"已公布范围 9.08–12.5 天，每周多次给药，一期\"},{\"label\":\"VK2735\",\"value\":250,\"note\":\"已公布范围约 170–250 小时，单次给药，一期\"},{\"label\":\"Enicepatide\",\"value\":151,\"note\":\"已公布范围：多次给药后 130–151 小时，单次给药后 123–139 小时，一期\"},{\"label\":\"替尔泊肽\",\"value\":120,\"note\":\"约 5 天，美国处方信息\"}]","每个已公布范围的上限，来源以天为单位的已换算为小时。替尔泊肽只有一个约 5 天的数值。人群、剂量和研究设计各不相同，数据来自不同研究，不是头对头比较。来源：替尔泊肽美国处方信息；礼来壁报 P-175，Psych Congress 2026；Viking Therapeutics，2023 年 3 月；Chakravarthy 等，Molecular Metabolism 2025。","已报告的最长平均半衰期（小时）"," 小时",[],{"type":44,"tag":45,"props":445,"children":446},{},[447],{"type":49,"value":448},"三项研究的耐受性数据对不上号。Brenipatide 25% 的胃肠道事件发生率，是在一个以男性为主的小样本中测得的，而安慰剂组也是同样的比例。在 VK2735 的诱导期，恶心和呕吐的报告明显更多，而 Viking 自己也说这项研究的剂量递增是加速的。Enicepatide 目前还未能检索到已公布的具体发生率，只有一个停药比例。半衰期更长或许能解释一部分差异，但剂量、加量速度、人群和研究时长同样可能是原因。",{"type":44,"tag":107,"props":450,"children":452},{"id":451},"哪些能比哪些不能比",[453],{"type":49,"value":454},"哪些能比，哪些不能比",{"type":44,"tag":45,"props":456,"children":457},{},[458],{"type":49,"value":459},"下表汇总了每家公司已经公布的内容。表中每一项都是在研药物。",{"type":44,"tag":461,"props":462,"children":463},"table",{},[464,497],{"type":44,"tag":465,"props":466,"children":467},"thead",{},[468],{"type":44,"tag":469,"props":470,"children":471},"tr",{},[472,476,483,490],{"type":44,"tag":473,"props":474,"children":475},"th",{},[],{"type":44,"tag":473,"props":477,"children":478},{},[479],{"type":44,"tag":60,"props":480,"children":481},{"href":62},[482],{"type":49,"value":65},{"type":44,"tag":473,"props":484,"children":485},{},[486],{"type":44,"tag":60,"props":487,"children":488},{"href":73},[489],{"type":49,"value":76},{"type":44,"tag":473,"props":491,"children":492},{},[493],{"type":44,"tag":60,"props":494,"children":495},{"href":84},[496],{"type":49,"value":87},{"type":44,"tag":498,"props":499,"children":500},"tbody",{},[501,525,546,569,591,613,636],{"type":44,"tag":469,"props":502,"children":503},{},[504,510,515,520],{"type":44,"tag":505,"props":506,"children":507},"td",{},[508],{"type":49,"value":509},"公司",{"type":44,"tag":505,"props":511,"children":512},{},[513],{"type":49,"value":514},"礼来",{"type":44,"tag":505,"props":516,"children":517},{},[518],{"type":49,"value":519},"Viking Therapeutics",{"type":44,"tag":505,"props":521,"children":522},{},[523],{"type":49,"value":524},"罗氏",{"type":44,"tag":469,"props":526,"children":527},{},[528,533,538,542],{"type":44,"tag":505,"props":529,"children":530},{},[531],{"type":49,"value":532},"最高研发阶段",{"type":44,"tag":505,"props":534,"children":535},{},[536],{"type":49,"value":537},"三期",{"type":44,"tag":505,"props":539,"children":540},{},[541],{"type":49,"value":537},{"type":44,"tag":505,"props":543,"children":544},{},[545],{"type":49,"value":537},{"type":44,"tag":469,"props":547,"children":548},{},[549,554,559,564],{"type":44,"tag":505,"props":550,"children":551},{},[552],{"type":49,"value":553},"已登记试验中的适应证",{"type":44,"tag":505,"props":555,"children":556},{},[557],{"type":49,"value":558},"酒精使用障碍、重度抑郁症（三期）；另外八种精神、成瘾、肠道和呼吸道疾病（二期）",{"type":44,"tag":505,"props":560,"children":561},{},[562],{"type":49,"value":563},"肥胖；肥胖合并 2 型糖尿病",{"type":44,"tag":505,"props":565,"children":566},{},[567],{"type":49,"value":568},"肥胖或超重，伴或不伴 2 型糖尿病（三期）；2 型糖尿病合并超重或肥胖（二期）",{"type":44,"tag":469,"props":570,"children":571},{},[572,576,581,586],{"type":44,"tag":505,"props":573,"children":574},{},[575],{"type":49,"value":377},{"type":44,"tag":505,"props":577,"children":578},{},[579],{"type":49,"value":580},"9.08–12.5 天",{"type":44,"tag":505,"props":582,"children":583},{},[584],{"type":49,"value":585},"单次给药后约 170–250 小时",{"type":44,"tag":505,"props":587,"children":588},{},[589],{"type":49,"value":590},"约 123–151 小时",{"type":44,"tag":469,"props":592,"children":593},{},[594,598,603,608],{"type":44,"tag":505,"props":595,"children":596},{},[597],{"type":49,"value":384},{"type":44,"tag":505,"props":599,"children":600},{},[601],{"type":49,"value":602},"未报告",{"type":44,"tag":505,"props":604,"children":605},{},[606],{"type":49,"value":607},"约 75–90 小时",{"type":44,"tag":505,"props":609,"children":610},{},[611],{"type":49,"value":612},"较高剂量下约 24 小时",{"type":44,"tag":469,"props":614,"children":615},{},[616,621,626,631],{"type":44,"tag":505,"props":617,"children":618},{},[619],{"type":49,"value":620},"最新数据",{"type":44,"tag":505,"props":622,"children":623},{},[624],{"type":49,"value":625},"一期壁报，Psych Congress，2026 年 9 月",{"type":44,"tag":505,"props":627,"children":628},{},[629],{"type":49,"value":630},"一期维持研究 VK2735-102（NCT07838740），2026 年 9 月 22 日",{"type":44,"tag":505,"props":632,"children":633},{},[634],{"type":49,"value":635},"2 型糖尿病二期，2026 年 9 月 22 日",{"type":44,"tag":469,"props":637,"children":638},{},[639,644,649,653],{"type":44,"tag":505,"props":640,"children":641},{},[642],{"type":49,"value":643},"状态",{"type":44,"tag":505,"props":645,"children":646},{},[647],{"type":49,"value":648},"任何地方均未获批",{"type":44,"tag":505,"props":650,"children":651},{},[652],{"type":49,"value":648},{"type":44,"tag":505,"props":654,"children":655},{},[656],{"type":49,"value":648},{"type":44,"tag":45,"props":658,"children":659},{},[660],{"type":49,"value":661},"目前以具体数字公布的减重结果，涉及的人群和时长都不相同。Enicepatide 的 15.5% 是 2 型糖尿病患者用药 48 周后的结果。VK2735 的 17.8% 和 21.7% 分别是肥胖但无糖尿病的人在 21 周和 33 周后的结果。Brenipatide 的壁报只有图表，没有数字，而且给药只持续到第 78 天，大约 11 周。",{"type":44,"tag":296,"props":663,"children":668},{"bars":664,"caption":665,"highlight":666,"title":667,"unit":279},"[{\"label\":\"Enicepatide，最高试验剂量\",\"value\":-15.5,\"note\":\"二期，2 型糖尿病，48 周，整个试验 n = 447\"},{\"label\":\"VK2735，17.5 mg 组，第 21 周\",\"value\":-17.8,\"note\":\"一期，肥胖，21 周，n = 118\"},{\"label\":\"VK2735，17.5 mg 组，第 33 周\",\"value\":-21.7,\"note\":\"一期，肥胖，33 周，n = 13\"}]","数据来自不同研究，不是头对头比较：人群、时长和分析方法都不同。Brenipatide 未列入，因为礼来没有印出确切数字。来源：罗氏临时公告，2026 年 9 月 22 日；Viking Therapeutics，顶线结果演示资料，2026 年 9 月。","Enicepatide，最高试验剂量","最新研究中报告的体重变化",[],{"type":44,"tag":45,"props":670,"children":671},{},[672],{"type":49,"value":673},"有三点可以比较。三个分子都作用于同样的两种受体。三者都设计为每周注射一次或间隔更长。而且三者目前都还是未获批准的在研物质。",{"type":44,"tag":45,"props":675,"children":676},{},[677],{"type":49,"value":678},"有三点无法比较。第一是患者：一项研究是糖尿病患者，另一项是肥胖人群，第三项里还有一部分是体重正常的人。第二是时间：Brenipatide 给药 11 周，VK2735 最长 33 周，Enicepatide 48 周。第三是每项研究提出的问题。礼来寻找的是用于非代谢性疾病的剂量范围，Viking 测试的是维持方案，罗氏测试的是血糖控制。凭这些数据无法给三个分子排出名次。要排名次，需要在同一项试验里直接比较，而目前未能检索到这样的试验。",{"type":44,"tag":45,"props":680,"children":681},{},[682,684,690],{"type":49,"value":683},"在体育领域，这个问题根本不存在，因为三者都没有获批。凡是未经任何政府批准用于人体治疗的物质，都归入世界反兴奋剂机构（WADA）禁用清单的 S0 类，任何时候都禁用。我们关于",{"type":44,"tag":60,"props":685,"children":687},{"href":686},"\u002Fpeptides-banned-in-sport",[688],{"type":49,"value":689},"体育运动中禁用的肽类",{"type":49,"value":691},"的概述解释了这一类别。",{"type":44,"tag":107,"props":693,"children":695},{"id":694},"常见问题",[696],{"type":49,"value":694},{"type":44,"tag":698,"props":699,"children":701},"h3",{"id":700},"brenipatide-是什么",[702],{"type":49,"value":20},{"type":44,"tag":45,"props":704,"children":705},{},[706],{"type":49,"value":21},{"type":44,"tag":698,"props":708,"children":710},{"id":709},"brenipatide-在临床试验中登记了哪些适应证",[711],{"type":49,"value":23},{"type":44,"tag":45,"props":713,"children":714},{},[715],{"type":49,"value":24},{"type":44,"tag":698,"props":717,"children":719},{"id":718},"vk2735-的维持研究测了什么",[720],{"type":49,"value":26},{"type":44,"tag":45,"props":722,"children":723},{},[724],{"type":49,"value":27},{"type":44,"tag":698,"props":726,"children":728},{"id":727},"vk2735-减少注射频率后减掉的体重保住了多少",[729],{"type":49,"value":29},{"type":44,"tag":45,"props":731,"children":732},{},[733],{"type":49,"value":30},{"type":44,"tag":698,"props":735,"children":737},{"id":736},"罗氏公布的-enicepatide-2-型糖尿病数据是什么",[738],{"type":49,"value":32},{"type":44,"tag":45,"props":740,"children":741},{},[742],{"type":49,"value":33},{"type":44,"tag":698,"props":744,"children":746},{"id":745},"brenipatidevk2735-和-enicepatide-的半衰期与替尔泊肽相比如何",[747],{"type":49,"value":35},{"type":44,"tag":45,"props":749,"children":750},{},[751],{"type":49,"value":36},{"type":44,"tag":698,"props":753,"children":755},{"id":754},"brenipatidevk2735-或-enicepatide-获批了吗体育比赛中允许使用吗",[756],{"type":49,"value":38},{"type":44,"tag":45,"props":758,"children":759},{},[760],{"type":49,"value":39},{"type":44,"tag":107,"props":762,"children":764},{"id":763},"参考来源",[765],{"type":49,"value":763},{"type":44,"tag":388,"props":767,"children":768},{},[769,782,794,805,817,828,839,850,861,872,884,895,906,917,928,940,951,963],{"type":44,"tag":392,"props":770,"children":771},{},[772,774],{"type":49,"value":773},"Eli Lilly and Company, ",{"type":44,"tag":60,"props":775,"children":779},{"href":776,"rel":777},"https:\u002F\u002Fassets.ctfassets.net\u002Fmpejy6umgthp\u002F1DBu0eLHcS9NjjpujOaamF\u002Ff0d57d38b14a73d659c3504020088e79\u002FBrenipatide_a_GIP_GLP-1_Receptor_Agonist_DV-041369-MDD.pdf",[778],"nofollow",[780],{"type":49,"value":781},"Brenipatide, a GIP\u002FGLP-1 Receptor Agonist: Clinical Data Supporting Dose Selection for Substance Use, Psychiatric and Immunologic Disorders (poster P-175, Psych Congress 2026)",{"type":44,"tag":392,"props":783,"children":784},{},[785,787],{"type":49,"value":786},"ClinicalTrials.gov, ",{"type":44,"tag":60,"props":788,"children":791},{"href":789,"rel":790},"https:\u002F\u002Fclinicaltrials.gov\u002Fstudy\u002FNCT06606106",[778],[792],{"type":49,"value":793},"NCT06606106: A Study of LY3537031 in Overweight, Obese, and Healthy Participants",{"type":44,"tag":392,"props":795,"children":796},{},[797,798],{"type":49,"value":786},{"type":44,"tag":60,"props":799,"children":802},{"href":800,"rel":801},"https:\u002F\u002Fclinicaltrials.gov\u002Fsearch?intr=brenipatide",[778],[803],{"type":49,"value":804},"Registered studies with brenipatide",{"type":44,"tag":392,"props":806,"children":807},{},[808,810],{"type":49,"value":809},"Viking Therapeutics, ",{"type":44,"tag":60,"props":811,"children":814},{"href":812,"rel":813},"https:\u002F\u002Fir.vikingtherapeutics.com\u002F2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens",[778],[815],{"type":49,"value":816},"Positive Topline Results from Maintenance Study of GLP-1\u002FGIP Agonist VK2735 (22 September 2026)",{"type":44,"tag":392,"props":818,"children":819},{},[820,821],{"type":49,"value":809},{"type":44,"tag":60,"props":822,"children":825},{"href":823,"rel":824},"https:\u002F\u002Ffilecache.investorroom.com\u002Fmr5ir_vikingtherapeutics\u002F313\u002FMaintenance%20Study%20Presentation.pdf",[778],[826],{"type":49,"value":827},"VK2735-102 Maintenance Study: Topline Results (presentation, September 2026)",{"type":44,"tag":392,"props":829,"children":830},{},[831,832],{"type":49,"value":809},{"type":44,"tag":60,"props":833,"children":836},{"href":834,"rel":835},"https:\u002F\u002Fir.vikingtherapeutics.com\u002F2023-03-28-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735",[778],[837],{"type":49,"value":838},"Results from Phase 1 Clinical Trial of Dual GLP-1\u002FGIP Receptor Agonist VK2735 (28 March 2023)",{"type":44,"tag":392,"props":840,"children":841},{},[842,843],{"type":49,"value":786},{"type":44,"tag":60,"props":844,"children":847},{"href":845,"rel":846},"https:\u002F\u002Fclinicaltrials.gov\u002Fstudy\u002FNCT07838740",[778],[848],{"type":49,"value":849},"NCT07838740: A Phase 1 Study of VK2735 in Obese Adults Without Comorbidities (VK2735-102)",{"type":44,"tag":392,"props":851,"children":852},{},[853,854],{"type":49,"value":786},{"type":44,"tag":60,"props":855,"children":858},{"href":856,"rel":857},"https:\u002F\u002Fclinicaltrials.gov\u002Fstudy\u002FNCT07104500",[778],[859],{"type":49,"value":860},"NCT07104500: VK2735 for Weight Management Phase 3 (VANQUISH 1)",{"type":44,"tag":392,"props":862,"children":863},{},[864,865],{"type":49,"value":786},{"type":44,"tag":60,"props":866,"children":869},{"href":867,"rel":868},"https:\u002F\u002Fclinicaltrials.gov\u002Fstudy\u002FNCT07104383",[778],[870],{"type":49,"value":871},"NCT07104383: VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)",{"type":44,"tag":392,"props":873,"children":874},{},[875,877],{"type":49,"value":876},"Roche, ",{"type":44,"tag":60,"props":878,"children":881},{"href":879,"rel":880},"https:\u002F\u002Fwww.roche.com\u002Fmedia\u002Freleases\u002Fmed-cor-2026-09-22",[778],[882],{"type":49,"value":883},"Positive Phase II results for dual GLP-1\u002FGIP receptor agonist enicepatide in people living with type 2 diabetes and overweight or obesity (22 September 2026)",{"type":44,"tag":392,"props":885,"children":886},{},[887,888],{"type":49,"value":876},{"type":44,"tag":60,"props":889,"children":892},{"href":890,"rel":891},"https:\u002F\u002Fwww.roche.com\u002Fmedia\u002Freleases\u002Fmed-cor-2026-01-27",[778],[893],{"type":49,"value":894},"Positive Phase II results for its dual GLP-1\u002FGIP receptor agonist CT-388 (27 January 2026)",{"type":44,"tag":392,"props":896,"children":897},{},[898,899],{"type":49,"value":786},{"type":44,"tag":60,"props":900,"children":903},{"href":901,"rel":902},"https:\u002F\u002Fclinicaltrials.gov\u002Fstudy\u002FNCT06628362",[778],[904],{"type":49,"value":905},"NCT06628362: A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes",{"type":44,"tag":392,"props":907,"children":908},{},[909,910],{"type":49,"value":786},{"type":44,"tag":60,"props":911,"children":914},{"href":912,"rel":913},"https:\u002F\u002Fclinicaltrials.gov\u002Fstudy\u002FNCT07351045",[778],[915],{"type":49,"value":916},"NCT07351045: ENITH-1",{"type":44,"tag":392,"props":918,"children":919},{},[920,921],{"type":49,"value":786},{"type":44,"tag":60,"props":922,"children":925},{"href":923,"rel":924},"https:\u002F\u002Fclinicaltrials.gov\u002Fstudy\u002FNCT07351058",[778],[926],{"type":49,"value":927},"NCT07351058: ENITH-2",{"type":44,"tag":392,"props":929,"children":930},{},[931,933],{"type":49,"value":932},"Chakravarthy et al., Molecular Metabolism 2025, ",{"type":44,"tag":60,"props":934,"children":937},{"href":935,"rel":936},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC12771327\u002F",[778],[938],{"type":49,"value":939},"Effects of CT-388, a once-weekly signaling-biased dual GLP-1\u002FGIP receptor agonist, on weight loss and glycemic control in preclinical models and participants with obesity",{"type":44,"tag":392,"props":941,"children":942},{},[943,944],{"type":49,"value":773},{"type":44,"tag":60,"props":945,"children":948},{"href":946,"rel":947},"https:\u002F\u002Fpi.lilly.com\u002Fus\u002Fmounjaro-uspi.pdf",[778],[949],{"type":49,"value":950},"Tirzepatide injection, US prescribing information",{"type":44,"tag":392,"props":952,"children":953},{},[954,956],{"type":49,"value":955},"World Anti-Doping Agency, ",{"type":44,"tag":60,"props":957,"children":960},{"href":958,"rel":959},"https:\u002F\u002Fwww.wada-ama.org\u002Fen\u002Fprohibited-list",[778],[961],{"type":49,"value":962},"The Prohibited List",{"type":44,"tag":392,"props":964,"children":965},{},[966,968],{"type":49,"value":967},"The Incretin Space (secondary source), ",{"type":44,"tag":60,"props":969,"children":972},{"href":970,"rel":971},"https:\u002F\u002Fthe-incretins.beehiiv.com\u002Fp\u002Fbrenipatide-vk2735-and-enicepatide",[778],[973],{"type":49,"value":974},"Brenipatide, VK2735 and Enicepatide (24 September 2026)",{"title":7,"searchDepth":976,"depth":976,"links":977},2,[978,979,980,981,982,983,984,994],{"id":109,"depth":976,"text":112},{"id":162,"depth":976,"text":165},{"id":227,"depth":976,"text":230},{"id":319,"depth":976,"text":322},{"id":364,"depth":976,"text":367},{"id":451,"depth":976,"text":454},{"id":694,"depth":976,"text":694,"children":985},[986,988,989,990,991,992,993],{"id":700,"depth":987,"text":20},3,{"id":709,"depth":987,"text":23},{"id":718,"depth":987,"text":26},{"id":727,"depth":987,"text":29},{"id":736,"depth":987,"text":32},{"id":745,"depth":987,"text":35},{"id":754,"depth":987,"text":38},{"id":763,"depth":976,"text":763},"markdown","content:blog:zh:gip-glp1-dual-agonists-brenipatide-vk2735-enicepatide.md","content","blog\u002Fzh\u002Fgip-glp1-dual-agonists-brenipatide-vk2735-enicepatide.md","blog\u002Fzh\u002Fgip-glp1-dual-agonists-brenipatide-vk2735-enicepatide","md"]